author-photo

Jean-Pierre Marie

All India Institute of Medical Sciences

166

Papers

4175

Citations

Citation Trend

Filter By

Papers (114) Sort By

Journal Conference Others

Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (6)
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

2018 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (3)
Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Low dose clofarabine in combination with a standard remission induction in patients 18-60 years with previously untreated intermediate and bad risk acute myeloid leukemia or high risk myelodysplastic syndrome: combined Phase I/II results of the EORTC/GIMEMA AML-14A Trial

2016 Haematologica
Show All
- Source
- Cite
- Save
Citations (3)
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

2015 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (9)
Protéines ABC : toujours un rôle à jouer dans les leucémies aiguës myéloïdes ?

2014
Show All
- Source
- Cite
- Save
Citations (0)
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial

2014 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (20)
Long-term imatinib maintenance therapy for adult Philadelphia positive acute lymphoblastic leukemia

2014 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Clofarabine in combination with a standard remission induction regimen in patients 18-60 years old previously untreated intermediate an bad risk actue myelogenous leukemia (AML) or high risk myelodysplasia (MDS): combined phase I/II results of the EORTC/Gimema AML-14A trial

2014 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)